Seres Therapeutics 817565CD4 Bond
1S9 Stock | EUR 0.84 0.01 1.20% |
Seres Therapeutics holds a debt-to-equity ratio of 0.233. . Seres Therapeutics' financial risk is the risk to Seres Therapeutics stockholders that is caused by an increase in debt.
Asset vs Debt
Equity vs Debt
Seres Therapeutics' liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Seres Therapeutics' cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Seres Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect Seres Therapeutics' stakeholders.
For most companies, including Seres Therapeutics, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for Seres Therapeutics, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, Seres Therapeutics' management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Seres |
Given the importance of Seres Therapeutics' capital structure, the first step in the capital decision process is for the management of Seres Therapeutics to decide how much external capital it will need to raise to operate in a sustainable way. Once the amount of financing is determined, management needs to examine the financial markets to determine the terms in which the company can boost capital. This move is crucial to the process because the market environment may reduce the ability of Seres Therapeutics to issue bonds at a reasonable cost.
Popular Name | Seres Therapeutics SCI Corp 4625 |
Equity ISIN Code | US81750R1023 |
Bond Issue ISIN Code | US817565CD49 |
S&P Rating | Others |
Maturity Date | Others |
Issuance Date | Others |
Coupon | 4.625 % |
Seres Therapeutics Outstanding Bond Obligations
Dana 575 percent | US235822AB96 | Details | |
Volcan Compania Minera | USP98047AC08 | Details | |
Boeing Co 2196 | US097023DG73 | Details | |
HSBC Holdings PLC | US404280DR76 | Details | |
MPLX LP 4875 | US55336VAG59 | Details | |
MPLX LP 4125 | US55336VAK61 | Details | |
MPLX LP 52 | US55336VAL45 | Details | |
Morgan Stanley 3591 | US61744YAK47 | Details | |
SCI Corp 4625 | US817565CD49 | Details | |
US817565CG79 | US817565CG79 | Details | |
SCI Corp 5125 | US817565CE22 | Details | |
SERVICE P INTL | US817565CF96 | Details | |
Morgan Stanley 3971 | US61744YAL20 | Details | |
MGM Resorts International | US552953CD18 | Details | |
Valero Energy Partners | US91914JAA07 | Details | |
SCI Corp 75 | US817565BT00 | Details |
Understaning Seres Therapeutics Use of Financial Leverage
Seres Therapeutics' financial leverage ratio helps determine the effect of debt on the overall profitability of the company. It measures Seres Therapeutics' total debt position, including all outstanding debt obligations, and compares it with Seres Therapeutics' equity. Financial leverage can amplify the potential profits to Seres Therapeutics' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if Seres Therapeutics is unable to cover its debt costs.
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts. SERES THERAPEUT operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 155 people. Please read more on our technical analysis page.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Seres Stock
When determining whether Seres Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Seres Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Seres Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Seres Therapeutics Stock:Check out the analysis of Seres Therapeutics Fundamentals Over Time. For more detail on how to invest in Seres Stock please use our How to Invest in Seres Therapeutics guide.You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
What is Financial Leverage?
Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.Leverage and Capital Costs
The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.Benefits of Financial Leverage
Leverage provides the following benefits for companies:- Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
- It provides a variety of financing sources by which the firm can achieve its target earnings.
- Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.